Monitor the integration of Avadel and the ramp-up of LUMRYZ sales, as the company transitions from profitability to a projected net loss in 2026 due to acquisition accounting. The success of alixorexton's phase 3 trials will be critical for long-term value creation.
ALKS drugs
ALKS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Feb 25 $31.03entry
- T+1 · 9mo ago −0.90%α −0.36% · $30.75
- T+5 · 9mo ago −6.03%α −4.93% · $29.16
- T+20 · 8mo ago −5.41%α −0.18% · $29.35
- T+60 · 6mo ago +19.19%α +12.24% · $36.98
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Alkermes reported 2025 total revenues of $1.48 billion and diluted GAAP EPS of $1.43, with a 9% year-over-year increase in proprietary product sales. The company expects a GAAP net loss in 2026 due to acquisition-related costs from the Avadel deal, despite projecting revenue growth to $1.73-$1.84 billion. The acquisition of Avadel strengthens its sleep medicine portfolio with LUMRYZ and supports the development of alixorexton.
Key Financial Metrics
Key Facts
- 2025 total revenue was $1.48 billion, down from $1.56 billion in 2024
- 2025 GAAP net income was $242 million, down from $367 million in 2024
- 2026 guidance includes a projected GAAP net loss of $115-$135 million
- 2026 revenue guidance is $1.73-$1.84 billion, representing 17-24% growth
- Acquisition of Avadel closed in February 2026 for $775 million in cash and $1.525 billion in term loans
- LUMRYZ net sales expected to contribute $315-$335 million in 2026
Financial Impact
GAAP net loss of $115-$135 million in 2026 due to $150 million inventory step-up expense and $95-$105 million amortization from Avadel acquisition
Segment Breakdown
| Segment | Revenue | Growth |
|---|---|---|
| VIVITROL | $467.9M | +2.3% |
| ARISTADA | $370.0M | +6.9% |
| LYBALVI | $346.7M | +23.9% |
Risk Factors
- Integration risks from the Avadel acquisition
- Dilution from $1.525 billion in new debt
- Execution risk in launching and commercializing LUMRYZ
- Clinical development risk for alixorexton
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-068512 |
| Document: alks-20260225.htm | 0001193125-26-068512 |
| Document: alks-ex99_2.htm | 0001193125-26-068512 |
| Document: 0001193125-26-068512-index-headers.html | 0001193125-26-068512 |
| Document: 0001193125-26-068512-index.html | 0001193125-26-068512 |
| Document: 0001193125-26-068512.txt | 0001193125-26-068512 |
Track record
23 reports on ALKS
3 of 3 bullish or bearish reports moved the stock their way by T+60. Best: +25.88% at T+60 after the May 12, 2026 report. 3 of 4 went positive at some point.
Filters
- Nov 12, 20264d ago 8-K Neutral 4/10 Entry $46.98 Now $46.53 −0.96% settles Feb 10
- Nov 4, 202612d ago Institutional Cluster Neutral 3/10 Entry $44.54 Now $46.53 +4.47% settles Feb 3
- Nov 3, 202613d ago 144 Neutral 2/10 Entry $45.89 Now $46.53 +1.39% settles Feb 2
- Nov 3, 202613d ago 8-K Neutral 5/10 Entry $45.69 Now $46.53 +1.84% settles Feb 1
- Sep 21, 20268w ago 8-K Bullish 6/10 Entry $44.00 Now $46.53 +5.76% settles Dec 15
- Sep 16, 20268w ago 8-K Neutral 2/10 Entry $46.07 Now $46.53 +1.00% settles Dec 10
- Sep 3, 202610w ago Insider Cluster Neutral 2/10 Entry $46.10 Now $46.53 +0.93% settles Dec 1
- Aug 3, 202615w ago Insider Cluster Bearish 4/10 Entry $49.67 to $44.32 Now $46.53 +6.32% ▲ +10.77% +11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 2/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
- Aug 3, 202615w ago Insider Cluster Neutral 3/10 Entry $49.67 to $44.32 Now $46.53 −6.32% ▼ −10.77% −11.15% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers